- Home
- ATOS vs CCIF Comparison
ATOS vs CCIF Comparison
Compare ATOS & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- CCIF
- Stock Information
- Founded
- ATOS 2009
- CCIF 2011
- Country
- ATOS United States
- CCIF United States
- Employees
- ATOS N/A
- CCIF N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- CCIF Finance/Investors Services
- Sector
- ATOS Health Care
- CCIF Finance
- Exchange
- ATOS Nasdaq
- CCIF Nasdaq
- Market Cap
- ATOS 106.9M
- CCIF 110.4M
- IPO Year
- ATOS 2012
- CCIF N/A
- Fundamental
- Price
- ATOS $0.77
- CCIF $5.04
- Analyst Decision
- ATOS Strong Buy
- CCIF
- Analyst Count
- ATOS 3
- CCIF 0
- Target Price
- ATOS $6.25
- CCIF N/A
- AVG Volume (30 Days)
- ATOS 539.9K
- CCIF 76.9K
- Earning Date
- ATOS 11-12-2025
- CCIF 01-01-0001
- Dividend Yield
- ATOS N/A
- CCIF 25.90%
- EPS Growth
- ATOS N/A
- CCIF N/A
- EPS
- ATOS N/A
- CCIF N/A
- Revenue
- ATOS N/A
- CCIF N/A
- Revenue This Year
- ATOS N/A
- CCIF N/A
- Revenue Next Year
- ATOS N/A
- CCIF N/A
- P/E Ratio
- ATOS N/A
- CCIF N/A
- Revenue Growth
- ATOS N/A
- CCIF N/A
- 52 Week Low
- ATOS $0.55
- CCIF $7.43
- 52 Week High
- ATOS $1.36
- CCIF $10.16
- Technical
- Relative Strength Index (RSI)
- ATOS 34.80
- CCIF 43.17
- Support Level
- ATOS $0.77
- CCIF $4.69
- Resistance Level
- ATOS $0.85
- CCIF $5.27
- Average True Range (ATR)
- ATOS 0.05
- CCIF 0.13
- MACD
- ATOS -0.01
- CCIF -0.01
- Stochastic Oscillator
- ATOS 18.62
- CCIF 62.08
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.